Telisotuzumab vedotin is under clinical development by AbbVie and currently in Pre-Registration for Non-Small Cell Lung Cancer.

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) ...

Woman from Central Texas thought she had allergies. Then she learned she had lung cancer, although she never smoked.

The latest announcement is out from AstraZeneca ( (AZN) ).

Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer.

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That Special ...

Wendy Ketelsen knows how to paint a picture for people, especially about a challenging year that she never could have ...

A home-based exercise program boosted exercise capacity and quality of life among patients after lung cancer surgery but did not improve self-reported physical function, a new study found.

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) withdraw EU marketing application for lung cancer therapy Dato-DXd. Read more ...

The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma ...

AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung ...